Table 2

Summary of all cell counts recorded

AZA

MMF

No IS

Hemoglobin, mmol/l

7.9 (5.5-10.4)

8.2 (5.4-10.7)

8.2 (4.5-10.7)

Platelets/µl

238 (48-459)

252 (136-404)

223 (96-379)

Leukocytes

4855 (2,060-10,160)

5970 (2,640-15,550)

5225 (2,080-9,050)

Lymphocytes/µl

987 (200-3,790)

1080 (360-3,010)

1330 (300-2,910)

B cells %

4.5 (0.6-31.3)* ^§§§

9.4 (0.6-40.1)*

11.8 (3.6-28.9)^§§§

B cells/µl

44(3-662)** ^§§§

113(4-462)**

119 (40-460)^§§§

T % of L

76 (28-93)*

63 (24-85)*

64 (42,2-84,5)

T/µl

584 (180-3,286)

640 (89-2,468)

807 (162-2,104)

CD4⁺ %

73 (39-82)

71 (41-92)

69 (33-92)

CD4⁺/µl

430 (85-1,709)

466 (61-2,021)

518 (106-1,514)

CD8⁺ %

19 (7-46)

22 (3-48)

22 (2-60)

CD8⁺/µl

127 (25-1,410)

144 (12-696)

207 (19-604)

CD4^-/CD8^- %

6 (2-18)

6 (2-11)

5 (2-20)

CD4^-/CD8^- /µl

41 (8-136)

41 (2-139)

46 (4-137)

Results are presented as median (range). Statistically significant differences detected between cell counts of patients taking azathioprine (AZA) and mycophenolate mofetil (MMF) (*P < 0.05, **P < 0.01, ***P < 0.001) and AZA compared to patients not taking immunosuppressive therapy ^§P < 0.05, ^§§P < 0.01, ^§§§P < 0.001 (Dunn's multiple comparison test).

Eickenberg et al. Arthritis Research & Therapy 2012 14:R110   doi:10.1186/ar3835